Background: The present study aims to investigate the levels of salivary procalcitonin (ProCT) in patients with different periodontal diseases.
Methods: Seventy-two non-smokers are included in this study: 21 individuals with chronic periodontitis (CP), 14 individuals with generalized aggressive periodontitis (GAgP), 18 individuals with gingivitis (G), and 19 periodontally healthy (H) participants. Clinical periodontal parameters, including probing depth (PD), clinical attachment level (CAL), plaque index, and gingival index (GI), were assessed in all participants. Saliva samples were collected and examined for evaluating ProCT levels.
Results: It was found that the median (interquartile range) salivary ProCT level was lowest in the H group: 0.00 (0.09) ng/mL; followed by the G group: 0.09 (0.11) ng/mL; the CP group: 0.15 (0.29) ng/mL; and highest in the GAgP group 0.28 (0.68) ng/mL. These differences were statistically significant between the H group and the other groups (P <0.05). There were positive correlations between the mean salivary ProCT level and GI, CAL, and PD.
Conclusion: According to the present results, ProCT might play a role during periodontal inflammation, and an elevated salivary ProCT level is suggested as a potential biomarker for periodontal diseases.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1902/jop.2015.130751 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
All-in-one microfluidic immunosensing device for rapid and end-to-end determination of salivary biomarkers of cardiovascular diseases.
Biosens Bioelectron
March 2025
School of Materials Science and Chemical Engineering, Ningbo University, Ningbo, Zhejiang, 315200, China. Electronic address:
Routine screening for cardiovascular diseases (CVDs) through point-of-care assays for at-home or community-based testing of salivary biomarkers can significantly improve patient outcomes. However, its translatability has been hindered by a dearth of biosensing devices that streamline assay procedures for rapid biomarker quantitation. To address this challenge through end-to-end engineering, we developed an in-house, all-in-one microfluidic immunosensing device that integrates on-chip vibration-enhanced incubation, magnetic-assisted separation using immune magnetic bead probes, and colorimetric readout via absorbance measurements.
View Article and Find Full Text PDFUpregulation of CRISP3 and its clinical values in adult sepsis: a comprehensive analysis based on microarrays and a two-retrospective-cohort study.
Front Immunol
December 2024
State Key Laboratory of Trauma, Burn and Combined Injury, Third Military Medical University, Chongqing, China.
Background: Current lines of evidence indicate that cysteine-rich secretory protein 3 (CRISP3) is an immunoregulatory factor. Nevertheless, no study has explored the relationships between the values of CRISP3 and sepsis.
Methods: We conducted a comprehensive literature search and meta-analysis from the Gene Expression Omnibus (GEO) and ArrayExpress to determine the expression of CRISP3 in sepsis patients.
Evaluation of Salivary Biomarkers and Spirometry for Diagnosing COPD in Non-Smokers and Smokers of Polish Origin.
Biomedicines
May 2024
Cancer Biomarker and Cytokines Laboratory Unit, Maria Skłodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.
Chronic obstructive pulmonary disease (COPD) is a prevalent respiratory condition with global implications. Accurate and timely diagnosis is critical; however, traditional diagnostic methods (based on spirometry) show limitations, prompting the search for predictive biomarkers and modern diagnostic techniques. This study explored the validation of COPD-related biomarkers (C-reactive protein, procalcitonin, neutrophil elastase, and alpha-1 antitrypsin) in saliva.
View Article and Find Full Text PDFProcalcitonin for Early Detection of Pharyngocutaneous Fistula after Total Laryngectomy: A Pilot Study.
Cancers (Basel)
February 2024
Unit of Otorhinolaryngology, Department of Mental and Physical Health and Preventive Medicine, University Luigi Vanvitelli, 80131 Naples, Italy.
Article Synopsis
- The study aimed to determine if procalcitonin (PCT) can be an early indicator of pharyngocutaneous fistulas (PCF) in head and neck cancer patients who had total laryngectomy.
- Conducted between January 2019 and March 2022, the study monitored blood chemistry, including PCT levels, at several key intervals: before surgery and on days 5 and 20 post-operation, plus when PCF symptoms appeared.
- The results indicated that PCT levels significantly differed between patients with and without PCF, suggesting it could be a valuable tool for early detection of this complication and aiding in appropriate antibiotic treatment.
Can the mucosal attacks of Behçet's disease be predicted?
Arch Dermatol Res
January 2024
University of Health Sciences Etlik City Hospital, Dermatology Clinic, Ankara, 06170, Turkey.
The primary objective of this study was to investigate the association between disease activity and serum and salivary procalcitonin (Pct) levels in patients with Behçet's disease (BD). The study included patients diagnosed with BD and age-matched healthy volunteers (N: 48, N: 32). Serum and salivary Pct levels were quantified using enzyme-linked immunosorbent assay (ELISA) in the laboratories of Diskapi Yildirim Beyazit Training and Research Hospital.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!